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The fully protected octapeptide VII with the amino acid se-
quence of the human insulin B23-ao chain has been synthesized by 
the condensation of the N-terminal tripeptide I and C-terminal 
pentapeptide VI fragments which were prepared stepwise. The 
N-terminal group of VII was protected by the benzyloxycarbonyl 
group, whereas all the other functions of VII were blocked by the 
use of the tert-butyloxycarbonyl and tert-butyl group, resp~ctively. 
Catalytic hydrogenation of VII gave the partially protected octa-
peptide VIII. 
Tl;le synthesis of the protected octapeptide containing the amino acid 
sequence of the carboxyl terminal portion of the human insulin B chain has 
been reported from several laboratories1- 4 ; the preparations differ in the pattern 
after which the peptide chain was built, as well as in the type and number 
of blocking groups. Recently, Obermeier and Geiger4 described a new semi-
synthesis of human insulin starting from porcine insulin; the procedure involves 
the use of a partially protected human insulin B23- 3o octapeptide derivative in 
which the £-amino group of lysine, the hydroxy group of tyrosine and the 
hydroxy- and carboxy-functions of the C-terminal threonine are protected 
by tert-butyloxycarbonyl- and tert-butyl-group, respectively. The authors give 
the overall scheme after which the peptide was prepared and claim that 
details of this synthesis are to be published in a separate paper. 
We wish to report the preparation5 of the fully protected human insulin 
B23- 3o octapeptide derivative VII (Scheme 1.) which was obtained by coupling 
of the N-terminal tri- and C-terminal penta-peptide fragment (I and VI) through 
the active ester method. Product VII differs from the above peptide derivative 
in that the hydroxy group of the central threonyl residue (B27 of human insulin) 
has also been protected by a tert-butyl group. 
The ·C-terminal pentapeptide fragment VI was synthesized by the stepwise 
approach: the benzyloxycarbonyl group was used for the protection of a-amino 
acid functions, and acylated amino acids were activated by conversion into the 
corresponding N-hydroxysuccinimidyl or p-nitrophenyl esters. The benzyloxy-
carbonyl group was removed from the protected intermediates II-V by catalytic 
hydrogenation without addition of the acid equivalent, and the resulting free 
bases were used immediately in the next condensation step. The crude inter-
mediates showed on TLC (solvents A and B) one major and several very weak 
spots and were used in the next step without purification; samples of II-V 
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were passed through silica gel columns with solvent A or B and then cha-
racterized. 
Condensation of . VI, previously purified over a silica gel column with 
solvent B, with the N-protected tripeptide N-hydroxysuccinimide ester I gave 
the fully protected octapeptide VII. Selective deblocking of VII by catalytic 
hydrogenation afforded the final product VIII in which all the functions , except 
the amino group of N-terminal glycine, are protected with the acid-labile 
groups. Octapeptide derivatives VII and VIII were obtained in good yields as 
.crystalline compounds and were characterized by elemental- and amino acid-
-analysis, optical rotation and ir and NMR spectra. 
EXPERIMENTAL 
Melting points are uncorrected. The concentrations of solutions were carried 
out under reduced pressure in a rotary evaporator at minimum temperature. Column 
chromatography was done on silica gel (Merck, · 0.02-0.2 mm). TLC on Kiesel G 
(Merck) plates was used to monitor the purity of all intermediates; compounds with 
peptide bonds were detected by the chlorine-starch-iodine method, compounds with 
free amino group with ninhydrin, and N-acylated compounds with ninhydrin, after 
spraying the plates with 50/o HBr in acetic acid-ethanol (1 : 5) and heating. The 
solvent systems used: A benzene-ethyl acetate; B chloroform-methanol (proportions 
are given in the text). Optical rotations were determined at 20-25 °c. Proton NMR 
spectra were recorded on a Varian A-60A spectrometer with tetramethylsilane as 
the internal standard. Ir spectra were recorded on a Perkin-Elmer Model 137 spec-
trometer. 
N-Benzyloxycarbonyl-0-tert-butyl-L-tyrosine p-Nitrophenyl Ester 
The title compound was obtained in the standard way by condensation of 
N-benzyloxycarbonyl-O-tert-butyl-L-tyrosine6 (2.65 g) and p-nitrophenol (1.10 g) 
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in the presence of dicyclohexylcarbodi-imide (DCC, 1.48 g) in ethyl acetate (25 ml). 
After removal of dicyclohexylurea (DCHU) and the solvent, the residue was cry-
stallised from ethanol to give 2.47 g (70.3°/o) of the product with m. p. 85-86 °c. 
A second crystallisation afforded the analytical sample: m. p. 86-86.5 °C, [a]D + 10.5° 
(c 1.0, dioxan). NMR data (CDCl3): r 1.75-3.25 (m, 13 H, Ph+ 2 X C6H4), 4.62 (d, 
1 H, J = 7.5 Hz, removed by D20 exchange, NH), 4.88 (s, 2 H, PhCH20), 5.21 (q, 
1 H, changes to triplet on deuteration, CH of Tyr), 8.69 (s, 9 H, Me3COC). 
Anal. C27H28N20 7 (492.53) calc'd.: C 65.85; H 5.73; N 5.69°/o 
found: C 65.84; H 5.58; N 5.85°/o 
N-Benzyloxycarbonyl-glycyl-L-phenylalanyl-L-phenylalanine 
N-Hydroxysuccinimide Ester (I) 
To a cooled solution of N-benzyloxycarbonyl-glycyl-L-phenylalanyl-L-phenyla-
lanine7 (2.18 g) in dry dioxan (60 ml), N-hydroxysuccinimide (497 mg) was added 
followed by DCC (890 mg) . After 12 h at room temperature, DCHU was filtered 
off, the filtrate was concentrated (0.1 Torr)* and the residue was crystallised from 
ethyl acetate-ether; .Yield: 1.82 g, 70.0°/o, m. p. 116-118 °c, [a]o-28.5~ (c 1.0, MeOH). 
The compound decomposes on standing and should be used within several days. 
Anal. C32H32N40 8 (600.60) calc'd.: C 63.99; H 5.37; N 9.33°/o 
found: C 63.80; H 5.51; N 9.09°/o 
N 2-Benzyloxycarbonyl-N6-tert-butyloxycarbonyl-L-lysyl-O-tert-butyl-L-
-threonine tert-Butyl Ester (II) 
N-Benzyloxycarbonyl-0-tert-butyl-L-threonine tert-butyl ester8 (3.83 g, 10.5 
mmol) was hydrogenated for 2 h over 10°/o palladium-on-charcoal (400 mg) in 
methanol (40 ml), the catalyst was removed by centrifugation, the supernatant con-
centrated to dryness, and the residue was dried by the addition of methanol followed 
by evaporation. To the solution of thts residue in N,N-dimethylformamide (DMF, 
5 ml) was added at 0 °c N2- benzyloxycarbonyl-N6-tert-butyloxycarbonyl-L-lysine 
p-nitrophenyl ester9 (5.27 g, 10.5 mmol) in DMF (5 ml). After 24 h at 0 °c and 5 h 
at room temperature, the reaction mixture was diluted with cold water (30 ml) 
and extracted with ethyl acetate. The combined extracts were washed successively 
with saturated aqueous sodium chloride, 1 M ,ammonium hydroxide, water, 100/o 
aqueous citric acid and water, dried (Na2S04) and concentrated. The remaining 
viscous oil (5.76 g, 92.50/o) was used directly in the next step. 
A sample (300 mg) of II was passed through a silicagel column with benzene, 
benzene-ethyl acetate (2 : 1) and (1 : 1) as the eluents; the last solvent eluted II 
(260 mg) as a colourless syrup, [a]o + 6.7° (c 1.0, CHC13). NMR data (CDC13): r 2.68 
(s, 5 H , Ph), 4.90 (s, 2 H, PhCH20), 8.56, 8.58 (2 s, unresolved, 9 H + 9 H, Me3COOC 
and Me3COCON), 8.86 (s, Me3COC + downfield peak of MeCH doublet) . 
Anal. C31H51N30 8 (593.74) calc'd.: C 62.70 ; H 8.66; N 7.080/o 
found: C 62.79 ; H 8.75 ; N 7.320/o 
N-B enzy loxycar bony l-L-prol y l-N6-tert-buty loxyca rbon y l-L-l ysy l-O-tert-
-buty l-1-th reonine tert-Butyl Ester (III) 
The fully protected dipeptide II (5.70 g, 9.62 mmol) was deblocked by catalytic 
hydrogenation as described above. The oily residue was dissolved in DMF (5 ml), 
and to this solution N-benzyloxycarbonyl-L-proline N-hydroxysuccinimide ester10 
(3.33 g, 9.62 mmol) in DMF (5 ml) was added at O 0c . After 24 h at O oc and 5 h at 
room temperature, cold water was added, and the mixture was extracted with 
ethyl acetate. The combined extracts were washed with saturated aqueous sodium 
chloride, 100/o aqueous citric acid, water, saturated aqueous sodium hydrogen carbo-
nate and water, dried and concentrated. The remaining syrup (6.20 g, 93.00/o) was 
used directly in the next step. 
* Torr = 133.322 Pa 
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A sample (485 g) of crude III was passed through a silica gel (10 g) column with 
benzene-ethyl acetate (1 : 2) to give the product which still contained (TLC, solvent 
A , 2: 1) traces of impurities; the latter were removed from a solution of ethyl acetate 
by addition of a few drops of petroleum ether. After centrifugation the supernatant 
was evaporated to dryness, and the residue was dissolved in chloroform; subsequent 
addition of petroleum ether at 0 °C deposited III as colourless crystals, m. p. 
106-107 °C, [a]n - 38.6° (c 1.7, CHC13). NMR data (CDC13): -r 2.48-2.73 (m, 5 H, Ph), 
4.82 (s, 3 H, PhCH20CON + NH), 8.50, 8.56, 8.80 (3 s, unresolved, 30 H, Me3COOC, 
Me3COCON, Me3COC + MeCH doublet masked by the Me3C singlets). 
Anal. CaoH5sN409 (690.85) calc'd.: C 62.58 ; H 8.46 ; N 8.11°/o 
found: C 62.74; H 8.70; N 8.29°/o 
N-Benzyloxycarbonyl-0-tert-butyl-L-threonyl-L-prolyl-N6-tert-
-butyloxycarbonyl-L-lysyl-0-tert-butyl-L-threonine tert-Butyl Ester (IV) 
The fully protected tripeptide III (6.20 g, 8.95 mmol) was deblocked by catalytic 
hydrogenation as described above. The oily residue was dissolved in DMF (5 ml), 
and to this solution N-benzyloxycarbonyl-0-tert-butyl-L-threonine N-hydroxysuc-
cinimide ester11 (3.63 g, 8.95 mmol) in DMF (5 ml) was added at 0 °C. After 24 h 
at 0 °C and 5 h at room temperature, wafer was added, and the reaction mixture 
was further processed as described for III. After removal of the solvent, the product 
was obtained as a solid which was used directly in the next step. 
A sample of IV (360 mg) was passed through a silica gel column with benzl?ne 
and then benzene-ethyl acetate (2 : 1); the latter solvent eluted IV (300 mg) as a 
solid, [a]D- 30.0° (c 1.0, CHC1:1) . • 
Anal. C44H73Ns011 (848.06) calc'd.: C 62.31; H 8.68; N 8.26°/o 




The fully protected tetrapeptide IV (3.95 g, 4.65 mmol) was deblocked by cata-
lytic hydrogenation as described above. The oily residue was dissolved in DMF 
(5 ml), and to this solution N-benzyloxyca rbonyl-0-tert-butyl-L-tyrosine p-nitrophenyl 
ester (2.29 g, 4.65 mmol) in DMF (5 ml) was added at 0 °C. After 48 h at 0 °c and 
5 h at room temperature water was added, and the reaction mixture was further 
processed as described for the preparation of II. After removal of the solvent, the 
product was obtained as a solid, m. p. 77-79 ~c, [a]D -13.2° (c 1.4, CHCla), yield: 
4.44 g, 89. 70/o. 
A sample (80 mg) of V was passed through a silica gel column (5 g) with 
benzene, benzene-ethyl acetate (1 : 1) and (1 : 2) ; the last solvent eluted V as a chro-
matographically homogeneous syrup which solidified on drying over phosphorous 
pentoxide. 
Anal. C5;H90N6013 (1 ,067.34) calc'd: C 64.14; H 8.50 ; N 7.880/o 
found: C 63.93 ; H 8.50; N 8.0lQ/o 
O-tert-Butyl-L-tyrosyl-0-tert-butyl-L-threonyl-L-prolyl-N6-tert-
-butyloxycarbonyl-L-lysyl-0-tert-butyl-L-threonine tert-Butyl Ester (VI) 
The crude, fully protected pentapeptide V (3.57 g, 3.35 mmol) was deblocked by 
catalytic hydrogenation as described above, and, after the removal of catalyst and 
solvent, the free base (3.05 g, 97.00/o) was obtained as a solid. A portion of this 
material (600 mg) · was passed through a silica gel (20 g) column with solvent B 
(18 : 1) to give chromatographically homogeneous VI (510 mg) , m. p. 87-89 °c, [a]D 
-31.3° (c 1.1, CHC13). NMR data (CDC13): -r 3.02 (m, 4 H, J AA' = Jxx· = 9.0 Hz, 
CH2-CoH4-0), 8.57, 8.60 (2 s, unresolved, Me3COOC, Me3COCON), 8.70, 8.77, 8.86 
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(3 s, unresolved, Me3COC6H4, 2 x Me3COC and 2 X MeCH doublets masked by Me3C 
singlets) . 
Anal. C40Hs4N6011 (933.25) calc'd.: C 63.06; H 9.07; N 9.010/o 
found: C 63.33; H 8.87; N 9.270/o 
N-Benzyloxycarbonyl-glycyl-L-phenylalanyl-L-phenylalanyl-0-tert-butyl-
-L-tyrosyl-0-tert-butyl-L-threonyl-L-prolyl-N6-tert-butyloxycarbonyl-L-
-lysyl-0-tert-butyl-L-threonine tert-Butyl Ester (VII) 
To a solution of the purified pentapeptide base VI (632 mg, 0.68 mmol) in DMF 
(8 ml) the tripeptide active ester I (448 mg, 100/o excess) was added at 0 °c. After 
24 h at 0 °C and 5 h at room temperature cold water (20 ml) was added, the mixture 
was extracted with ethyl acetate, and the combined extracts were further processed 
as described for III. After removal of the solvent, the product was obtained as a 
solid foam (938 mg, 97.50/o), m. p. 124-144 frC which on TLC (solvent B, 18 : 1) showed 
a major (R1 - 0.6) and several v~ry weak spots. This material was passed through 
a silica gel (25 g) column with solvent B (18 : 1) to give chromatographically homo-
geneous VII (750 mg, 78.10/o), m. p . 153- 154 °c, [a)n - 31.5° (c 1.1, CHC13). v ~~~ 3370 
s (NH), 3000 s (Me, CH2, CH), 1660 and 1520 vs (amide I and II) , 1450 s , 1400 m 
and 1370 s (Me3C), 1160 s (C-0-C), 740 m and 700 s cm-1. NMR data (CDC13): 
r 2.58-3.00 (m, 19 H, 3 X Ph + C6H 4), 8.56, 8.58, 8.83 (3 s, unresolved, 51 H , MeaCOOC, 
Me3COCON, 3 X Me3COC and 2 X MeCH doublets masked by MeaC singlets). Amin,o 
acid analysis after acidic hydrolysis, expressed in molar ratio: Glyi.o Phe2.o Tyro.s 
Thri.9 Proi.o Lysu. 
Anal. C77H111N90 16 (1,418.73) calc'd. : C 65.18; H 7.89; N 8.890/o 
found: C 65.43 ; H 7.79; N 9.040/o 
Glycy'l-L-phenylalanyl-L-phenylalanyl-O-tert-butyl-L-tyrosyl-0-tert-
-butyl-L-threonyl-L-prolyl-N6-tert-butyloxycarbonyl-L-lysyl-0-tert-butyl-
-L-threonine tert-Butyl Ester (VIII) 
The fully protected octapeptide VII (518 mg, 0.366 mmol) was hydrogenated fo r 
2 h over 100/o palladium-on-charcoal (300 mg) in methanol- DMF (4 : 1, 20 ml) contain-
ing acetic acid (0.5 ml). The catalyst was centrifuged off, the supernatant concentrated, 
and to a solution of the residue in ethyl acetate petroleum ether was added at 0 °c. 
The precipitated octapeptide VIII (423 mg, 90°/o) had m. p . 137-140 °c (sinterring 
at 118 °C), [a)n - 40.7° (c 1.1, CHC13) and was chromatographically homogeneous (sol-
vent B, 18 : 1). v ~~ 3500 s and 3380 s (NH), 1645 vs and 1520 s (amide I and II), 
1450 m, 1400 m and 1370 m (Me3C), 1160 s, 740 m and 695 m cm-1• NMR da ta (CDC13) : 
r 2.50-2.73 (m, 14 H, 2 X Ph+ C6H4), 8.50, 8.67 and 8.80 (3 s, Me3COOC, Me3COCON 
and 3 X Me3COC + 2 X MeCH doublets masked by Me3C singlets). 
Anal. C69H 105N90 14 (1,284.60) calc'd.: C 64.51; H 8.24; N 9.810/o 
found: C 64.27; H 8.45; N 9.920/o 
A sample (10 mg) of VIII was deblocked by exposure to trifluoroacetic acid 
(1 ml) at O 0c for 30 min; this material was completely digested by bacterial protease 
(Sigma). 
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SAZETAK 
Sinteza zasticenih derivata oktapeptida cija sekvenca odgovara lancu B e3- 3o humanog 
insulina 
D. KegLevic, D. GoLes, M . Pongracic i S. Va1entekovic 
Potpuno zasticeni oktapeptid VII sintetiziran je kondenzacijom N-terminalnog 
tripeptida s C-terminalnim pentapeptidom metodom · aktivnog · estera. U spoju VII 
N-terminalna amino fm1kcija glicina zastiCena je s benziloksikarbonil skupinom; 
i::-amino skupina lizina s tert-butiloksikarbonil skupinom, dok su hidroksi funkcije tiro.:. 
zina i dva treonina te karboksi skupina C-terminalnog treonina blokirana s tert-butil 
skupinama. Katalitickim hidriranjem VII dobiven je N-terminalno slobodni oktapeptid 
VIII u kojemu su sve ostale funkcije zasticene skupinama koje su labitne u kiselom 
mediju. Sinteza C-terminalnog pentapeptid intermedijera izvedena je kondenzacijom 
po principu »glave na rep« preko aktivnih estera N-benziloksikarbonil-amino kise-
lina. Intermedijeri I-VI i produkti VII i VIII su potpuno karakterizirani. 
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